 | This articlemay incorporate text from alarge language model. It may includehallucinated information,copyright violations, claims notverified in cited sources,original research, orfictitious references. Any such material should beremoved, and content with anunencyclopedic tone should be rewritten.(November 2025) (Learn how and when to remove this message) |
 | |
| Clinical data | |
|---|---|
| Other names | SENS-111; SENS111; UR-63325; UR63325 |
| Routes of administration | Oral[1] |
| Drug class | HistamineH4 receptorantagonist |
| Legal status | |
| Legal status | |
| Identifiers | |
| CAS Number | |
| PubChemCID | |
| UNII | |
| Chemical and physical data | |
| Formula | C12H21N5 |
| Molar mass | 235.335 g·mol−1 |
| 3D model (JSmol) | |
| |
Seliforant (also known asSENS-111 orUR-63325) is aninvestigationalsmall-moleculedrug developed by Sensorion (originally by Palau Pharma) forinner-ear/vestibular disorders, particularlyvertigo andvestibular neuritis, and has also been cited as having potential fortinnitus andhearing loss indications.[2]
Seliforant was first developed as a first-in-classantagonist of thehistamine H4 receptor (H4R), areceptor subtype implicated in immune modulation and potentially neurosensory signalling.[1]
The drug was granted itsInternational Non-Proprietary Name (INN) "seliforant" by theWorld Health Organization in 2018.[2]
Seliforant functions byantagonising thehistamineH4 receptor (H4R).[1] H4 receptors are expressed in severaltissues includingimmune cells and may play roles inneurosensory signalling. The rationale for vestibular/ear indications is based on modulation of aberrant vestibular/inner-ear neuronal activity rather than conventionalantihistamine pathways.[3]
In human Phase 1/2 volunteer studies, seliforant was reported to be well tolerated, with mild to moderate events and nosedation reported.[5]